カルベニシリンナトリウム

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H317：アレルギー性皮膚反応を起こすおそれ

  H334：吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P272：汚染された作業衣は作業場から出さないこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P284：呼吸用保護具を着用すること。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P333+P313：皮膚刺激または発疹が生じた場合：医師の診断/手当てを 受けること。

カルベニシリンナトリウム 価格

MSDS Information

• Disodium [2S-(2alpha,5alpha,6beta)]-6-(carboxylatophenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

カルベニシリンナトリウム 化学特性,用途語,生産方法

• 外観

  白色～うすい緑黄色、結晶性粉末～粉末

• 溶解性

  水に溶ける。

• 効能

  抗生物質, 細胞壁合成阻害薬

• 使用上の注意

  不活性ガス封入

• 説明

  Carbenicillin is a broad-spectrum carboxypenicillin antibiotic. It is active against Gram-negative and certain Gram-positive bacteria, including S. pyogenes, S. epidermidis, P. mirabilis, P. vulgaris, E. coli, and P. aeruginosa (MICs = 0.19, 1.56, 1.56, 3.12, 3.12, and 50 μg/ml, respectively). It is also active against penicillinase-producing and non-producing strains of S. aureus (MICs = 1.56 and 12.5 μg/ml, respectively). Carbenicillin is protective against systemic S. pyogenes, P. vulgaris, E. coli, and S. aureus infection in a mouse model of systemic lethal infection with 50% protective dose (PD₅₀) values of 7.8, 224, 19.3, and 34 mg/kg, respectively. It also decreases viable colony counts in the kidney in a rat model of P. vulgaris or E. coli urinary tract infection when administered at a dose of 100 mg/kg. Formulations containing carbenicillin have previously been used in the treatment of upper and lower urinary tract infections and prostatitis.

• 化学的特性

  white Powder

• 使用

  Carbenicillin disodium salt is a water-soluble antibiotic which is effective against gram-negative bacteria.Carbenicillin disodium salt is widely utilized as an antibiotic which is used to control bacterial cell-wall synthesis by inactivating transpeptidases on the inner surface of the bacterial cell membrane. It has been involved in the study of the role of penicillin-sensitive transpeptidases in cell wall biosynthesis.

• 一般的な説明

  Carbenicillin was synthesized by Brain et al. of Beecham Research Laboratories in 1965. It was the first synthetic penicillin to show activity against Pseudomonas aeruginosa. Although its activity against the microorganism is not strong (MIC = 25 – 100 μg/mL), it is widely used against P. aeruginosa infections because of its low toxicity and the lack of other antibiotics suitable for use against this microorganism. Carbenicillin is mainly used clinically to treat urinary tract and respiratory tract infections and sepsis caused by Proteus, Escherichia coli, Klebsiella, and Pseudomonas aeruginosa.

• 臨床応用

  Carbenicillin disodium, disodium α-carboxybenzylpenicillin(Geopen, Pyopen), is a semisynthetic penicillin releasedin the United States in 1970, which was introduced inEngland and first reported by Ancred et al. in 1967.Examination of its structure shows that it differs from ampicillinin having an ionizable carboxyl group rather than anamino group substituted on the α-carbon atom of the benzylside chain. Carbenicillin has a broad range of antimicrobialactivity, broader than any other known penicillin, a propertyattributed to the unique carboxyl group. It has been proposedthat the carboxyl group improves penetration of themolecule through cell wall barriers of Gram-negativebacilli, compared with other penicillins.
  Carbenicillin is not stable in acids and is inactivated bypenicillinase. It is a malonic acid derivative and, as such, decarboxylatesreadily to penicillin G, which is acid labile.Solutions of the disodium salt should be freshly prepared but,when refrigerated, may be kept for 2 weeks. It must be administeredby injection and is usually given intravenously.
  Carbenicillin has been effective in the treatment of systemicand urinary tract infections caused by P. aeruginosa,indole-producing Proteus spp., and Providencia spp., all ofwhich are resistant to ampicillin. The low toxicity of carbenicillin,with the exception of allergic sensitivity, permits theuse of large dosages in serious infections. Most cliniciansprefer to use a combination of carbenicillin and gentamicinfor serious pseudomonal and mixed coliform infections. Thetwo antibiotics are chemically incompatible, however, andshould never be combined in an intravenous solution.

カルベニシリンナトリウム 上流と下流の製品情報

カルベニシリンナトリウム 生産企業

Global(491)Suppliers

カルベニシリンナトリウム スペクトルデータ(¹HNMR、MS)

4800-94-6, カルベニシリンナトリウム キーワード